Longevity
What PEARL Actually Showed
A year-long randomized trial of low-dose rapamycin returned a quieter result than the longevity press has acknowledged.
On reading the Lancet Commission’s ’45 per cent’ figure correctly
The 2024 Lancet Commission on dementia prevention is substantive and important. The public life of its headline number — that...
What the evidence on GLP-1 medications and extended life actually says
The cardiovascular and mortality evidence on semaglutide and its class is now substantial in defined at-risk populations. Reading that as...
What GLP-1 Drugs Actually Do to Ageing
The weight-loss story is the popular story. The metabolic and inflammatory story is more consequential — and less settled than...
What the psychedelic evidence actually supports — and what the executive order does not address
An executive order signed with a podcaster in the room and a quip about wanting some directs fifty million dollars...
The Nitrogen Debt
The world's food supply depends on a chemistry invented in 1909 and a supply chain routed through three contested straits....
The first human de-ageing trial is running. Nobody is asking the right questions.
Life Biosciences received FDA approval in January 2026 for the first Phase 1 human trial of partial epigenetic reprogramming. The...
Ageing is not damage. It is a conversation that stops.
For three decades, longevity science pursued molecular defects. The emerging systems biology consensus holds a different premise: the body does...
The Longest Awkward Age
We built a world for people who die on time. Now that they aren't, nobody quite knows what to do....
